Nithin K, Jayadevan P M, Raveendran Vysakh
Department of Radiation Oncology, Rajagiri Hospital, Aluva, Kerala, India.
Department of Radiation Oncology, Advanced Centre for Treatment and Education in Cancer, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
J Med Phys. 2025 Jul-Sep;50(3):590-595. doi: 10.4103/jmp.jmp_97_25. Epub 2025 Sep 29.
The application of ISORAD diode detectors in treatments like total body irradiation (TBI), where small fractions of potentially lethal doses are delivered, lacks comprehensive clarity and requires further investigation. The study evaluates the feasibility of using ISORAD diode detectors as in vivo dosimeter for extended source to surface distance (SSD) treatments like TBI, despite a 250 cm limit in the manufacturer's specifications. Four identical ISORAD-1163 n-type cylindrical diode detectors manufactured by Sun Nuclear Corporation were studied for their operational characteristics and compared with 0.6cc Farmer chamber. The performance evaluation involved assessing reproducibility, linearity, field size dependence, and dose rate dependence at an SSD of 100 cm, extending up to 400 cm. Postirradiation signal drift, short-term reproducibility, and Signal Stability were monitored at extended SSDs. Directional dependence was evaluated in both the axial plane and transverse plane at 100 cm SSD. A diode was then used as an in vivo dosimeter for the bilateral TBI technique at 380 cm SSD. Acceptable dose rate effect (<0.91%), linearity (<0.99%), and reproducibility (<0.19%) with minimum deviations in postirradiation signal drift (<0.09%) and signal consistency (<0.09%) were observed up to 400 cm SSD for all diodes. Significant directional dependence of more than 1.1% was observed beyond ± 30° in the transverse plane of the detector, while it was insignificant in the axial plane. In vivo measurements of TBI patients with diodes at head, neck, umbilicus, chest, ankle, and shoulder showed that the maximum dose difference in the calculated and actual diode readings did not exceed 8.5%. Operational characteristics of in vivo diodes revealed to be consistent up to 400 cm SSD, supporting their applicability for in vivo measurements in TBI patients.
在诸如全身照射(TBI)这类给予少量潜在致死剂量的治疗中,ISORAD二极管探测器的应用缺乏全面的清晰度,需要进一步研究。该研究评估了将ISORAD二极管探测器用作体内剂量计用于TBI等扩展源皮距(SSD)治疗的可行性,尽管制造商规格中有250厘米的限制。研究了由太阳核公司制造的四个相同的ISORAD - 1163 n型圆柱形二极管探测器的运行特性,并与0.6cc Farmer电离室进行了比较。性能评估包括在100厘米至400厘米的SSD下评估再现性、线性、射野大小依赖性和剂量率依赖性。在扩展SSD下监测辐照后信号漂移、短期再现性和信号稳定性。在100厘米SSD下,在轴向平面和横向平面评估方向依赖性。然后将一个二极管用作380厘米SSD下双侧TBI技术的体内剂量计。对于所有二极管,在高达400厘米SSD时观察到可接受的剂量率效应(<0.91%)、线性(<0.99%)和再现性(<0.19%),辐照后信号漂移的偏差最小(<0.09%),信号一致性偏差最小(<0.09%)。在探测器横向平面±30°以外观察到超过1.1%的显著方向依赖性,而在轴向平面则不显著。用二极管对TBI患者的头部、颈部、脐部、胸部、脚踝和肩部进行体内测量表明,计算的和实际的二极管读数中的最大剂量差异不超过8.5%。体内二极管的运行特性显示在高达400厘米SSD时是一致的,支持它们在TBI患者体内测量中的适用性。